Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF/EVG Rectal Insert Safety and PK Study
NCT04047420Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir alafenamide and elvitegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Grade 2 and Higher Adverse Events at 76 days and Elvitegravir Concentration in Blood at 72 hours. Started Dec 2019; status: completed.
02
Drugs
tenofovir alafenamideelvitegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04047420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047420.